

Durata Therapeutics, Inc.
Form SC TO-C
October 06, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 6, 2014 (October 5, 2014)

ACTAVIS plc

(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction

of incorporation)

000-55075
(Commission

File Number)
1 Grand Canal Square, Docklands

98-1114402
(I.R.S. Employer

Identification No.)

Edgar Filing: Durata Therapeutics, Inc. - Form SC TO-C

Dublin 2, Ireland

(Address of principal executive offices and Zip Code)

(862) 261-7000

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On October 6, 2014, ACTAVIS plc (Actavis) and Durata Therapeutics, Inc. (Durata) issued a joint press release announcing the execution of an Agreement and Plan of Merger (the Merger Agreement), dated October 5, 2014, by and among Delaware Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Actavis, Actavis W.C. Holding Inc., a Delaware corporation and a wholly owned subsidiary of Actavis, and Durata. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Additionally, on October 6, 2014, Actavis distributed the following materials, copies of which are attached hereto as exhibits and incorporated herein by reference:

Memorandum to Employees (Exhibit 99.2)

Notice to Investors

The tender offer for the outstanding common stock of Durata referred to in this 8-K and related exhibits has not yet commenced. The description contained in this 8-K and related exhibits is neither an offer to purchase nor a solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of Durata common stock will be made pursuant to an offer to purchase and related materials that Actavis intends to file with the Securities and Exchange Commission. At the time the offer is commenced, Actavis will file a tender offer statement on Schedule TO with the Securities and Exchange Commission, and thereafter Durata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. The tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement will contain important information that should be read carefully and considered before any decision is made with respect to the tender offer. Additionally, Durata and Actavis will file other relevant materials in connection with the proposed acquisition of Durata by Actavis pursuant to the terms of the merger agreement. These materials will be sent free of charge to all stockholders of Durata when available. In addition, all of these materials (and all other materials filed by Durata with the Securities and Exchange Commission) will be available at no charge from the Securities and Exchange Commission through its website at www.sec.gov. Free copies of the offer to purchase, the related letter of transmittal and certain other offering documents will be made available by Actavis and when available may be obtained by directing a request to Actavis's Investor Relations Department at (862) 261-7488. Investors and security holders may also obtain free copies of the documents filed with the Securities and Exchange Commission by Durata by contacting Durata Investor Relations at (312) 219-7017.

INVESTORS AND SHAREHOLDERS OF DURATA ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER OR MERGER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description
------------	--------------------

Edgar Filing: Durata Therapeutics, Inc. - Form SC TO-C

- 99.1 Press release dated October 6, 2014.
- 99.2 Memorandum to Employees distributed on October 6, 2014 by Actavis plc.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACTAVIS plc

Date: October 6, 2014

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: Chief Legal Officer and Secretary

EXHIBIT INDEX

Exhibit

No.	Description
99.1	Press release dated October 6, 2014.
99.2	Memorandum to Employees distributed on October 6, 2014 by Actavis plc.